Plasma lipid peroxidation and progression of disability in multiple sclerosis

被引:58
作者
Koch, M.
Mostert, J.
Arutjunyan, A. V.
Stepanov, M.
Teelken, A.
Heersema, D.
De Keyser, J.
机构
[1] Univ Groningen, Med Ctr, Dept Neurol, NL-9713 GZ Groningen, Netherlands
[2] Russian Acad Med Sci, DO Ott Res Inst Obstet & Gynaecol, Lab Perinatal Biochem, St Petersburg, Russia
关键词
multiple sclerosis; oxidative stress; prognosis; progression;
D O I
10.1111/j.1468-1331.2007.01739.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Oxidative stress has been implicated in the pathophysiology of multiple sclerosis (MS), but its relation to disease progression is uncertain. To evaluate the relationship of plasma lipid peroxidation with progression of disability in MS, we measured blood plasma fluorescent lipid peroxidation products (PFLPP) levels in 23 patients with RRMS with a benign course, 32 with secondary progressive MS, 24 with primary progressive MS and 30 healthy controls. None of the patients had a relapse within the previous 3 months. Progression of disability was evaluated during a follow-up period of 5 years by the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Severity Score (MSSS). We found plasma PFLPP levels elevated in patients with MS compared with controls (P < 0.0001), but there was no difference between patients with a benign and progressive disease course. There was no correlation between PFLPP levels and worsening of disability on the EDSS and speed of progression on the MSSS. Our data suggest that there is no relation between the degree of oxidative stress in plasma and progression of disability in MS.
引用
收藏
页码:529 / 533
页数:5
相关论文
共 26 条
[1]   Neurodegenerative diseases and oxidative stress [J].
Barnham, KJ ;
Masters, CL ;
Bush, AI .
NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (03) :205-214
[2]   Lipoprotein oxidation, plasma total antioxidant capacity and homocysteine level in patients with multiple sclerosis [J].
Besler, HT ;
Çomoglu, S .
NUTRITIONAL NEUROSCIENCE, 2003, 6 (03) :189-196
[3]   Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences [J].
Bjartmar, C ;
Trapp, BD .
CURRENT OPINION IN NEUROLOGY, 2001, 14 (03) :271-278
[4]   Antioxidants in multiple sclerosis - Do they have a role in therapy? [J].
Carlson, Noel G. ;
Rose, John W. .
CNS DRUGS, 2006, 20 (06) :433-441
[5]   Age at disability milestones in multiple sclerosis [J].
Confavreux, C ;
Vukusic, S .
BRAIN, 2006, 129 :595-605
[6]   LIPID-PEROXIDATION PRODUCTS IN BIOLOGICAL TISSUES [J].
DILLARD, CJ ;
TAPPEL, AL .
FREE RADICAL BIOLOGY AND MEDICINE, 1989, 7 (02) :193-196
[7]   Increased levels of lipid hydroperoxides in plasma of patients with multiple sclerosis: a relationship with paraoxonase activity [J].
Ferretti, G ;
Bacchetti, T ;
Principi, F ;
Di Ludovico, F ;
Viti, B ;
Angeleri, VA ;
Danni, M ;
Provinciali, L .
MULTIPLE SCLEROSIS JOURNAL, 2005, 11 (06) :677-682
[8]   MEASUREMENT OF FLUORESCENT LIPID PEROXIDATION PRODUCTS IN BIOLOGICAL-SYSTEMS AND TISSUES [J].
FLETCHER, BL ;
DILLARD, CJ ;
TAPPEL, AL .
ANALYTICAL BIOCHEMISTRY, 1973, 52 (01) :1-9
[9]   The role of oxidative stress in the pathogenesis of multiple sclerosis: The need for effective antioxidant therapy [J].
Gilgun-Sherki, Y ;
Melamed, E ;
Offen, D .
JOURNAL OF NEUROLOGY, 2004, 251 (03) :261-268
[10]  
GLABINSKI A, 1993, ACTA NEUROL SCAND, V88, P174